Cell and Gene Therapy Strategic Roundup | June 24–July 29, 2026
Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…
Endocrinology Strategic Roundup | June 23–July 20, 2026
Strategic Developments and Competitive Shifts in Endocrinology Coverage Period:…
United Therapeutics’ Thymmune acquisition | Lucid Diligence Brief
United Therapeutics adds Thymmune’s iPSC thymic-cell platform to its…
Merck KGaA Bio-Techne Deal | Lucid Diligence Brief
Merck KGaA’s US$11.3bn Bio-Techne acquisition tests workflow depth, integration…
Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief
Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…
In Vivo CAR-T: Stress-Testing the Lilly–Kelonia Deal with AI-Powered Wargaming
Why the Lilly–Kelonia Deal Matters for In Vivo CAR-T Download the…
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash…
Cell and Gene Therapy Today—March 5, 2026
This is a weekly update in gene and cell therapy, covering key regulatory…
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…
Cell and Gene Therapy Today—February 19, 2026
This week's update in gene and cell therapy covers notable developments…
Cell and Gene Therapy Today—February 5, 2026
This week's Cell and Gene Therapy updatehighlights key regulatory actions,…
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…